Evidence map›Paper›PMID 25884224›Full record

ArticleBMC cancer2015

Sumoylation of Kif18A plays a role in regulating mitotic progression.

Feikun Yang, Yan Chen, Wei Dai

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Feikun YangDepartment of Environmental Medicine, New York University Langone Medical Center, 57 Old Forge Road, Tuxedo Park, NY, 10987, USA. yfk_10987@yahoo.com.
Yan ChenCenter for Drug Discovery, Northeastern University, 360 Huntington Avenue, Boston, MA, 02115, USA. yan.chen21@yahoo.com.
Wei DaiDepartment of Environmental Medicine, New York University Langone Medical Center, 57 Old Forge Road, Tuxedo Park, NY, 10987, USA. wei.dai@nyumc.org.
NYU Langone Health · USNortheastern University · US

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
RESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1M
Molecular mechanisms underlying chromosomal instability and aneuploidyR01CA090658 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAI, WEI · 2001 to 2012
$2.9M
Mechanisms of arsenic-induced chromosomal instability and carcinogenesisR01ES020591 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DAI, WEI · 2012 to 2016
$2.0M
Study of Anti-Survival signals in NF1R01CA153354 · NCI · NORTHEASTERN UNIVERSITY · PI CHEN, CHANGYAN · 2012 to 2017
$1.6M
Plk3 in lung cancerR03ES019929 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI XU, DAZHONG · 2011 to 2012
$160k
NCI NIH HHS CA090658NCI NIH HHS P30 CA016087NCI NIH HHS R01 CA090658NCI NIH HHS R01 CA153354NIEHS NIH HHS ES000260NIEHS NIH HHS ES019929NIEHS NIH HHS P30 ES000260NIEHS NIH HHS R01 ES020591NIEHS NIH HHS R03 ES019929
6 · The paper itself

Abstract

backgroundKif18A, the kinesin-8 motor protein, plays an essential role in regulating alignment of bi-oriented chromosomes at the midzone during mitosis. Kinesin proteins, including Kif18A, are often deregulated in many types of cancers and are thought to play a critical role in cancer progression. However, little is known about the post-translational modifications of Kif18A and their effects on its biological activity.

methodsKif18A was identified to be a SUMO2 acceptor by using Ni-IDA resin to precipitate proteins from cells stably expressing His6-SUMO2. To identify the potential lysine residues, multi-site directed mutagenesis together with transient transfection and Ni-IDA pull-down assay were carried out. The confocal time-lapse imaging and immunofluorescent staining were used to study the roles of SUMO2 modification on Kif18A's activity during the cell cycle.

resultsKif18A is covalently modified by SUMO2 during the cell cycle, and its sumoylation peaks at metaphase and then rapidly decreases upon anaphase onset. Mutational analysis identifies multiple lysine residues (K148, K442, K533, K660 and K683) as potential SUMO acceptors. The functional studies reveal that sumoylation of Kif18A has little effect on protein stability and subcellular localization. However, compared with the wild-type control, ectopic expression of SUMO-resistant mutants of Kif18A results in a significant delay of mitotic exit. Confocal microscopy shows that cells expressing SUMO-resistant Kif18A display a compromised dissociation of BubR1 from kinetochores after anaphase onset.

conclusionsOur studies reveal that sumoylation functions as an unidentified form of post-translational modification that regulates Kif18A activity during mitotic progression.

Indexed as

AnaphaseGene Expression Regulation, NeoplasticHeLa CellsHumansKinesinsKinetochoresMitosisProtein Processing, Post-TranslationalProtein Serine-Threonine KinasesSmall Ubiquitin-Related Modifier ProteinsSumoylationBUB1 protein, humanKIF18A protein, humanKinesinsProtein Serine-Threonine KinasesSmall Ubiquitin-Related Modifier ProteinsSUMO2 protein, human

Identifiers

PMID25884224
PMCPMC4389313
OpenAlexW2035028290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.